Phases, active trials: Phase 1: 18, Phase 2: 52, Phase 3: 38, Other: 14
Regeneron builds antibody medicines. Its discovery platform has produced approved drugs in immunology, oncology, and eye disease.
Immunology. Dupixent (dupilumab), co-developed with Sanofi, is approved for atopic dermatitis, asthma, COPD, eosinophilic esophagitis, and prurigo nodularis, among other indications. Trials continue in further diseases driven by the same IL-4 and IL-13 pathway.
Oncology. Libtayo (cemiplimab) is an approved PD-1 checkpoint inhibitor for cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. A bispecific antibody program, led by odronextamab (CD20xCD3), runs multiple trials in blood cancers.
Ophthalmology. Eylea and Eylea HD (aflibercept) are approved for wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion.
- Immunology / type 2 inflammation (IL-4/IL-13)
- Oncology (PD-1, bispecific antibodies)
- Ophthalmology (VEGF inhibition)
- Cardiovascular (PCSK9, Factor XI)
- Infectious disease / vaccines
- Dupixent (dupilumab): IL-4Rα, atopic dermatitis/asthma/COPD
- Libtayo (cemiplimab): PD-1, CSCC/BCC/NSCLC
- Odronextamab: CD20×CD3 bispecific, B-cell malignancies
- Eylea HD (aflibercept 8 mg): wet AMD, DME
- Praluent (alirocumab): PCSK9, LDL lowering
- REGN4461: leptin receptor agonist, rare obesity
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and… NCT06149286 | Primary completion moved at least 2 years 3 months later Primary endpoint reworded | Recruiting |
14 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than… NCT06190951 | Nov 2, 2026 · Estimated | Phase 2 |
7 more on the Completions page. See the calendar →
Monitor the Regeneron pipeline daily
Get a daily digest when Regeneron registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Melanoma | 6 |
| Advanced Solid Tumors | 3 |
| Atrial Fibrillation (AF) | 3 |
| Fallopian Tube Cancer | 3 |
| Multiple Myeloma | 3 |
| Non-small Cell Lung Cancer | 3 |
| Overweight or Obesity | 3 |
| Paroxysmal Nocturnal Hemoglobinuria | 3 |
Regeneron's Dupixent expansion trials, targeting further IL-4/IL-13-driven indications such as chronic rhinosinusitis variants and pediatric populations, generate a steady flow of new registrations. The bispecific antibody program in hematology (odronextamab and successors) is one lymphoma-focused BD teams watch closely.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Regeneron's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Regeneron may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Regeneron pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult… NCT07477704 | Active, Not Recruiting | Enrollment closed, study ongoing | 2026-10-16 |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial… NCT07430956 | Recruiting | Trial sites expanded: 35 → 44 locations | 2026-10-15 |
| Study of Olatorepatide in Adult Participants Living With Overweight or Obesity… NCT07685808 | Recruiting | Trial sites expanded: 18 → 21 locations | 2026-10-14 |
| A Study Investigating Subcutaneously Administered Pozelimab in Combination With… NCT06541704 | Recruiting | Trial sites expanded: 225 → 231 locations | 2026-10-14 |
| REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis NCT07410117 | Recruiting | Trial sites expanded: 20 → 23 locations | 2026-10-14 |
Each trial page shows every change DataLookout has recorded for that trial.